Latest Articles

PCSK9 Inhibitors in Cardiovascular Disease

Perceptions and Barriers on the use of PCSK9 inhibitors

PCSK9i and Prevention of CVD

The synopsis of a Cochrane Systematic review on PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.

PCSK9 inhibitors and ACS

Closed-loop insulin delivery during exercise in people with T1DM

Management of Patients With Very High Cardiovascular Risk Eligible for PCSK9 Inhibitor Treatment: 1-year Outcomes of The PERI-DYS Study

Lp(a) as ASCVD risk factor

Management of athletes and active people with diabetes - The American Medical Society for Sports Medicine (AMSSM) scientific statement

Lp(a) and PCSK9 inhibition in nominally controlled LDL-C patients